GB201504502D0 - Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers - Google Patents

Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Info

Publication number
GB201504502D0
GB201504502D0 GB201504502A GB201504502A GB201504502D0 GB 201504502 D0 GB201504502 D0 GB 201504502D0 GB 201504502 A GB201504502 A GB 201504502A GB 201504502 A GB201504502 A GB 201504502A GB 201504502 D0 GB201504502 D0 GB 201504502D0
Authority
GB
United Kingdom
Prior art keywords
peptides
cancers
combination
pancreatic cancer
immunotherapy against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201504502A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to GB201504502A priority Critical patent/GB201504502D0/en
Publication of GB201504502D0 publication Critical patent/GB201504502D0/en
Priority to MYPI2020007212A priority patent/MY199500A/en
Priority to CN202110838669.8A priority patent/CN113563456A/zh
Priority to UAA201707771A priority patent/UA123392C2/uk
Priority to SG10202001404VA priority patent/SG10202001404VA/en
Priority to PCT/EP2016/055817 priority patent/WO2016146751A1/en
Priority to JP2017547530A priority patent/JP6715856B2/ja
Priority to TW109140069A priority patent/TWI755158B/zh
Priority to KR1020177025935A priority patent/KR102718168B1/ko
Priority to CN201680015234.0A priority patent/CN107428810B/zh
Priority to BR112017019217-9A priority patent/BR112017019217A2/pt
Priority to CR20210232A priority patent/CR20210232A/es
Priority to CA2979506A priority patent/CA2979506A1/en
Priority to AU2016232140A priority patent/AU2016232140B2/en
Priority to TW109140068A priority patent/TWI769586B/zh
Priority to EA201791853A priority patent/EA037783B1/ru
Priority to CR20170419A priority patent/CR20170419A/es
Priority to TW109140067A priority patent/TWI755157B/zh
Priority to MA40713A priority patent/MA40713A1/fr
Priority to TW105108310A priority patent/TWI726872B/zh
Priority to MYPI2017702731A priority patent/MY190083A/en
Priority to MA46647A priority patent/MA46647A1/fr
Priority to CR20210233A priority patent/CR20210233A/es
Priority to CR20210234A priority patent/CR20210234A/es
Priority to HK18107389.4A priority patent/HK1247842A1/zh
Priority to PE2017001485A priority patent/PE20171515A1/es
Priority to KR1020247033261A priority patent/KR20240151873A/ko
Priority to MX2017011857A priority patent/MX2017011857A/es
Priority to EP16710223.5A priority patent/EP3270952A1/en
Priority to SG11201706155XA priority patent/SG11201706155XA/en
Priority to MYPI2019007608A priority patent/MY199259A/en
Priority to MA46648A priority patent/MA46648B2/fr
Priority to US15/073,528 priority patent/US10076560B2/en
Priority to ZA2017/05219A priority patent/ZA201705219B/en
Priority to PH12017501467A priority patent/PH12017501467A1/en
Priority to IL254081A priority patent/IL254081B/en
Priority to CONC2017/0009101A priority patent/CO2017009101A2/es
Priority to MX2022005570A priority patent/MX2022005570A/es
Priority to CL2017002346A priority patent/CL2017002346A1/es
Priority to US15/869,471 priority patent/US10357551B2/en
Priority to CL2018002427A priority patent/CL2018002427A1/es
Priority to US16/409,393 priority patent/US10449239B1/en
Priority to US16/563,151 priority patent/US10576135B2/en
Priority to US16/563,096 priority patent/US10561718B2/en
Priority to US16/748,350 priority patent/US10668138B1/en
Priority to JP2020047156A priority patent/JP6990935B2/ja
Priority to US16/839,412 priority patent/US10729755B1/en
Priority to US16/851,627 priority patent/US10792350B2/en
Priority to CL2020001675A priority patent/CL2020001675A1/es
Priority to US16/911,069 priority patent/US11007257B2/en
Priority to US16/915,323 priority patent/US11007258B2/en
Priority to AU2020220073A priority patent/AU2020220073B2/en
Priority to AU2020220070A priority patent/AU2020220070B2/en
Priority to AU2020220071A priority patent/AU2020220071B2/en
Priority to AU2020220072A priority patent/AU2020220072B2/en
Priority to US17/018,695 priority patent/US10898561B2/en
Priority to IL280879A priority patent/IL280879A/en
Priority to ARP210100473A priority patent/AR121588A2/es
Priority to ARP210100472A priority patent/AR121587A2/es
Priority to CL2021000624A priority patent/CL2021000624A1/es
Priority to CL2021000623A priority patent/CL2021000623A1/es
Priority to US17/229,556 priority patent/US11116826B2/en
Priority to US17/327,190 priority patent/US12214025B2/en
Priority to JP2021191620A priority patent/JP7478718B2/ja
Priority to US17/937,165 priority patent/US12295994B2/en
Priority to US17/937,268 priority patent/US12295995B2/en
Priority to US17/937,285 priority patent/US12295996B2/en
Priority to JP2024001298A priority patent/JP2024041860A/ja
Priority to US19/173,511 priority patent/US20250235519A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
GB201504502A 2015-03-17 2015-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers Ceased GB201504502D0 (en)

Priority Applications (69)

Application Number Priority Date Filing Date Title
GB201504502A GB201504502D0 (en) 2015-03-17 2015-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
MYPI2020007212A MY199500A (en) 2015-03-17 2016-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
CN202110838669.8A CN113563456A (zh) 2015-03-17 2016-03-17 用于胰腺癌和其他癌症免疫治疗的新型肽和肽组合物
UAA201707771A UA123392C2 (uk) 2015-03-17 2016-03-17 Пептид, здатний зв'язуватися з молекулою головного комплексу гістосумісності (mhc) людини i класу, та його застосування для лікування раку
SG10202001404VA SG10202001404VA (en) 2015-03-17 2016-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
PCT/EP2016/055817 WO2016146751A1 (en) 2015-03-17 2016-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
JP2017547530A JP6715856B2 (ja) 2015-03-17 2016-03-17 膵臓がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
TW109140069A TWI755158B (zh) 2015-03-17 2016-03-17 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合
KR1020177025935A KR102718168B1 (ko) 2015-03-17 2016-03-17 췌장암 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
CN201680015234.0A CN107428810B (zh) 2015-03-17 2016-03-17 用于胰腺癌和其他癌症免疫治疗的新型肽和肽组合物
BR112017019217-9A BR112017019217A2 (pt) 2015-03-17 2016-03-17 peptídeos e combinações de peptídeos para uso em imunoterapia do câncer de pâncreas e outros cânceres
CR20210232A CR20210232A (es) 2015-03-17 2016-03-17 NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)
CA2979506A CA2979506A1 (en) 2015-03-17 2016-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
AU2016232140A AU2016232140B2 (en) 2015-03-17 2016-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
TW109140068A TWI769586B (zh) 2015-03-17 2016-03-17 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合
EA201791853A EA037783B1 (ru) 2015-03-17 2016-03-17 Новые пептиды и комбинации пептидов для применения в иммунотерапии рака поджелудочной железы и других видов рака
CR20170419A CR20170419A (es) 2015-03-17 2016-03-17 Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
TW109140067A TWI755157B (zh) 2015-03-17 2016-03-17 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合
MA40713A MA40713A1 (fr) 2015-03-17 2016-03-17 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
TW105108310A TWI726872B (zh) 2015-03-17 2016-03-17 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合
MYPI2017702731A MY190083A (en) 2015-03-17 2016-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
MA46647A MA46647A1 (fr) 2015-03-17 2016-03-17 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
CR20210233A CR20210233A (es) 2015-03-17 2016-03-17 NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)
CR20210234A CR20210234A (es) 2015-03-17 2016-03-17 NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)
HK18107389.4A HK1247842A1 (zh) 2015-03-17 2016-03-17 用於胰腺癌和其他癌症免疫治疗的新型肽和肽组合物
PE2017001485A PE20171515A1 (es) 2015-03-17 2016-03-17 Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer
KR1020247033261A KR20240151873A (ko) 2015-03-17 2016-03-17 췌장암 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
MX2017011857A MX2017011857A (es) 2015-03-17 2016-03-17 Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer.
EP16710223.5A EP3270952A1 (en) 2015-03-17 2016-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
SG11201706155XA SG11201706155XA (en) 2015-03-17 2016-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
MYPI2019007608A MY199259A (en) 2015-03-17 2016-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
MA46648A MA46648B2 (fr) 2015-03-17 2016-03-17 Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
US15/073,528 US10076560B2 (en) 2015-03-17 2016-03-17 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
ZA2017/05219A ZA201705219B (en) 2015-03-17 2017-08-02 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
PH12017501467A PH12017501467A1 (en) 2015-03-17 2017-08-14 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
IL254081A IL254081B (en) 2015-03-17 2017-08-21 New peptides and a combination of peptides for immunotherapeutic use against pancreatic cancer and other types of cancer
CONC2017/0009101A CO2017009101A2 (es) 2015-03-17 2017-09-06 Péptidos y combinación de péptidos
MX2022005570A MX2022005570A (es) 2015-03-17 2017-09-14 Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el cancer de pancreas y otros tipos de cancer.
CL2017002346A CL2017002346A1 (es) 2015-03-17 2017-09-15 Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
US15/869,471 US10357551B2 (en) 2015-03-17 2018-01-12 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
CL2018002427A CL2018002427A1 (es) 2015-03-17 2018-08-24 Péptidos y combinación de péptidos para el uso de la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. (divisional solicitud 201702346)
US16/409,393 US10449239B1 (en) 2015-03-17 2019-05-10 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US16/563,151 US10576135B2 (en) 2015-03-17 2019-09-06 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US16/563,096 US10561718B2 (en) 2015-03-17 2019-09-06 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US16/748,350 US10668138B1 (en) 2015-03-17 2020-01-21 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
JP2020047156A JP6990935B2 (ja) 2015-03-17 2020-03-18 膵臓がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
US16/839,412 US10729755B1 (en) 2015-03-17 2020-04-03 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US16/851,627 US10792350B2 (en) 2015-03-17 2020-04-17 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
CL2020001675A CL2020001675A1 (es) 2015-03-17 2020-06-19 Péptidos asociados a tumor y su uso en la inmunoterapia contra el cáncer (divisional solicitud 201702346)
US16/911,069 US11007257B2 (en) 2015-03-17 2020-06-24 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US16/915,323 US11007258B2 (en) 2015-03-17 2020-06-29 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
AU2020220073A AU2020220073B2 (en) 2015-03-17 2020-08-18 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
AU2020220070A AU2020220070B2 (en) 2015-03-17 2020-08-18 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
AU2020220071A AU2020220071B2 (en) 2015-03-17 2020-08-18 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
AU2020220072A AU2020220072B2 (en) 2015-03-17 2020-08-18 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US17/018,695 US10898561B2 (en) 2015-03-17 2020-09-11 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
IL280879A IL280879A (en) 2015-03-17 2021-02-15 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
ARP210100473A AR121588A2 (es) 2015-03-17 2021-02-24 Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
ARP210100472A AR121587A2 (es) 2015-03-17 2021-02-24 Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
CL2021000624A CL2021000624A1 (es) 2015-03-17 2021-03-15 Péptidos asociados a tumor que se unen al complejo mayor de histocompatibilidad (mhc) y/o inducen la reacción cruzada de linfocitos t y sus usos en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201702346)
CL2021000623A CL2021000623A1 (es) 2015-03-17 2021-03-15 Péptidos asociados a tumor y sus usos en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201702346)
US17/229,556 US11116826B2 (en) 2015-03-17 2021-04-13 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US17/327,190 US12214025B2 (en) 2015-03-17 2021-05-21 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
JP2021191620A JP7478718B2 (ja) 2015-03-17 2021-11-25 膵臓がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
US17/937,165 US12295994B2 (en) 2015-03-17 2022-09-30 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US17/937,268 US12295995B2 (en) 2015-03-17 2022-09-30 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US17/937,285 US12295996B2 (en) 2015-03-17 2022-09-30 Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
JP2024001298A JP2024041860A (ja) 2015-03-17 2024-01-09 膵臓がんおよびその他のがんに対する免疫療法において使用するための新規ペプチドおよびペプチドの組み合わせ
US19/173,511 US20250235519A1 (en) 2015-03-17 2025-04-08 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201504502A GB201504502D0 (en) 2015-03-17 2015-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Publications (1)

Publication Number Publication Date
GB201504502D0 true GB201504502D0 (en) 2015-04-29

Family

ID=53016273

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201504502A Ceased GB201504502D0 (en) 2015-03-17 2015-03-17 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

Country Status (19)

Country Link
US (2) US10076560B2 (enExample)
EP (1) EP3270952A1 (enExample)
JP (1) JP6715856B2 (enExample)
KR (1) KR102718168B1 (enExample)
CN (2) CN107428810B (enExample)
AR (2) AR121587A2 (enExample)
AU (4) AU2016232140B2 (enExample)
BR (1) BR112017019217A2 (enExample)
CA (1) CA2979506A1 (enExample)
CR (3) CR20210233A (enExample)
EA (1) EA037783B1 (enExample)
GB (1) GB201504502D0 (enExample)
MA (3) MA46647A1 (enExample)
MX (1) MX2017011857A (enExample)
PE (1) PE20171515A1 (enExample)
SG (2) SG10202001404VA (enExample)
TW (2) TWI726872B (enExample)
UA (1) UA123392C2 (enExample)
WO (1) WO2016146751A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2943565B1 (en) 2013-01-14 2018-03-28 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
MY190083A (en) 2015-03-17 2022-03-25 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
CA3004830A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
MX2018007204A (es) 2015-12-16 2018-12-11 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno.
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
KR102639592B1 (ko) 2016-12-08 2024-02-21 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP3558327A4 (en) * 2016-12-21 2020-12-09 Fred Hutchinson Cancer Research Center SCAFFOLDING TO TREAT SOLID TUMOR CELLS AND EXHAUST VARIANTS
KR20240162609A (ko) * 2017-04-10 2024-11-15 이매틱스 바이오테크놀로지스 게엠베하 암에 대한 면역요법에 사용하기 위한 펩티드 및 그 조합
WO2018218137A1 (en) 2017-05-25 2018-11-29 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
ES2898210T3 (es) 2017-07-14 2022-03-04 Immatics Biotechnologies Gmbh Molécula de polipéptido con especificidad dual mejorada
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
AU2018348165B2 (en) 2017-10-10 2025-09-04 Seattle Project Corp. Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
MX2020008327A (es) 2018-02-09 2020-10-28 Immatics Us Inc Metodos para preparar celulas t.
AU2018410849B2 (en) 2018-02-27 2025-02-27 Leidos, Inc. PD-1 peptide inhibitors
WO2019175380A2 (en) * 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
US12098179B2 (en) 2018-03-16 2024-09-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
WO2020191172A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
JP7606471B2 (ja) 2019-05-22 2024-12-25 レイドス， インコーポレイテッド Ｌａｇ３結合ペプチド
PE20220164A1 (es) 2019-05-27 2022-01-28 Immatics Us Inc Vectores viricos y uso de los mismos en terapias celulares adoptivas
AU2020286756A1 (en) 2019-06-06 2022-01-27 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
AU2021225817A1 (en) 2020-02-24 2022-10-20 Immatics US, Inc. Methods for expanding T cells for the treatment of cancer and related malignancies
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
JP7744928B2 (ja) * 2020-04-29 2025-09-26 イージー バイオメッド カンパニー リミテッド 大腸癌の早期検出、治療応答性および予後の予測のための方法
JP7560850B2 (ja) * 2020-07-01 2024-10-03 学校法人関西医科大学 尿路系上皮腫瘍関連病変を検出するためのバイオマーカー
US11578102B2 (en) 2020-07-31 2023-02-14 Leidos, Inc. LAG3 binding peptides
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
US11987646B2 (en) 2020-10-12 2024-05-21 Leidos, Inc. Immunomodulatory peptides
CN112557347B (zh) * 2020-11-12 2023-10-24 渤海大学 一种黏液层中乳糜粒子迁移模型的制备及检测方法
CN112462066B (zh) * 2020-12-03 2023-05-19 中南大学湘雅医院 Fam3c蛋白及其特异性抗体在制备检测鼻咽癌试剂盒中的应用、试剂盒及其应用
TW202241938A (zh) 2020-12-31 2022-11-01 美商英麥提克斯股份有限公司 Ｃｄ８多肽、組合物及其使用方法
CN112760383B (zh) * 2021-03-02 2023-07-21 上海欧易生物医学科技有限公司 应用于肺腺癌细胞亚群的一组qRT-PCR内参基因及其应用
CN114163512B (zh) * 2021-03-24 2025-02-25 深圳市新靶向生物科技有限公司 一种与肝癌驱动基因突变相关的抗原肽组合及其应用
JP2024516699A (ja) 2021-05-05 2024-04-16 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｂｍａ０３１抗原結合ポリペプチド
US20240358831A1 (en) 2021-08-24 2024-10-31 Immatics US, Inc. Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
KR102618065B1 (ko) * 2021-12-10 2023-12-22 성균관대학교산학협력단 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단 방법
CN114214406A (zh) * 2021-12-15 2022-03-22 天津医科大学总医院 一种用于评价肿瘤患者免疫治疗反应性和评估肿瘤预后的三联标志物及其应用
JP2025516189A (ja) 2022-04-28 2025-05-27 イマティクス ユーエス，アイエヌシー． 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法
JP2025515603A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス，アイエヌシー． Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法
EP4514834A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
CN119724622B (zh) * 2024-11-25 2025-12-12 中国人民解放军总医院第五医学中心 一种评价ptt对胰腺癌治疗效果的方法、系统及设备

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610031A (en) * 1993-10-27 1997-03-11 The General Hospital Corporation B1k chain of laminin and methods of use
US6316213B1 (en) * 1997-03-19 2001-11-13 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian, breast and lung cancer
AU4158799A (en) * 1998-06-06 1999-12-30 Genostic Pharma Limited Probes used for genetic filing
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20040146519A1 (en) * 1999-12-10 2004-07-29 John Fikes Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
JP2003516344A (ja) * 1999-12-13 2003-05-13 エピミューン， インコーポレイテッド Ｈｌａクラスｉａ２腫瘍関連抗原ペプチドおよびワクチン組成物
CN1469926A (zh) * 2000-03-29 2004-01-21 科里克萨有限公司 治疗和诊断肺癌的组合物和方法
WO2003010327A2 (en) * 2001-02-21 2003-02-06 Curagen Corporation Novel proteins and nucleic acids encoding same
US20030021796A1 (en) * 2001-05-04 2003-01-30 Leszek Ignatowicz Method of enhancing T cell immunity by selection of antigen specific T cells
JP2003321494A (ja) * 2002-02-26 2003-11-11 Daiichi Fine Chemical Co Ltd プロｍｍｐ−７の活性化調節方法
EP2070949B1 (en) * 2002-06-10 2013-01-16 Vaccinex, Inc. C35 antibodies and their use in the treatment of cancer
JP2006516089A (ja) * 2002-10-02 2006-06-22 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
AU2003298014A1 (en) * 2002-12-04 2004-06-23 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
ES2556232T3 (es) * 2004-03-31 2016-01-14 International Institute Of Cancer Immunology, Inc. Péptidos antigénicos del cáncer derivados de WT1
SI1760089T1 (sl) * 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
GB0611116D0 (en) * 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
PL2562182T3 (pl) * 2007-07-27 2016-03-31 Immatics Biotechnologies Gmbh Nowe immunogenne epitopy do immunoterapii
EP2127664A1 (en) * 2008-02-15 2009-12-02 Max-Delbrück-Centrum Change of the load state of MHC molecules by dipeptides
CA2718830C (en) * 2008-03-31 2017-04-18 Kyoto University Method for proliferation of pluripotent stem cells
DK2119726T5 (en) * 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
WO2010047938A2 (en) * 2008-10-21 2010-04-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Mmp activation peptide detection in biological samples
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2011119484A1 (en) * 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
AU2012203810B2 (en) * 2011-06-22 2013-12-05 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
CA2844793A1 (en) * 2011-08-31 2013-03-07 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
EP2771349B1 (en) * 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
US20140065620A1 (en) * 2011-12-29 2014-03-06 Mayo Foundation For Medical Education And Research Nucleic acids for detecting breast cancer
TWI819228B (zh) * 2013-08-05 2023-10-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八）
CN104163862B (zh) * 2013-12-04 2017-02-08 魏敏杰 与人mhc‑i类分子结合的grp78多肽表位
CN104306976A (zh) * 2014-04-26 2015-01-28 深圳市康尔诺生物技术有限公司 一种高效的肿瘤个体化免疫治疗方法及其应用

Also Published As

Publication number Publication date
CN107428810A (zh) 2017-12-01
SG11201706155XA (en) 2017-09-28
AU2016232140B2 (en) 2020-07-02
US10076560B2 (en) 2018-09-18
CN107428810B (zh) 2022-08-19
CN113563456A (zh) 2021-10-29
AU2020220073A1 (en) 2020-09-03
US10357551B2 (en) 2019-07-23
MA46648B2 (fr) 2023-01-31
CR20170419A (es) 2017-11-22
AU2020220073B2 (en) 2021-10-14
EA037783B1 (ru) 2021-05-20
EA201791853A1 (ru) 2017-12-29
AU2020220072A1 (en) 2020-09-03
CR20210234A (es) 2021-06-25
JP6715856B2 (ja) 2020-07-01
SG10202001404VA (en) 2020-04-29
AR121587A2 (es) 2022-06-22
JP2018510628A (ja) 2018-04-19
TWI726872B (zh) 2021-05-11
BR112017019217A2 (pt) 2018-04-10
MA40713A1 (fr) 2018-11-30
EP3270952A1 (en) 2018-01-24
TW202124427A (zh) 2021-07-01
MA46648A1 (fr) 2021-02-26
US20170165335A1 (en) 2017-06-15
AU2020220072B2 (en) 2021-11-25
MX2017011857A (es) 2018-04-24
WO2016146751A1 (en) 2016-09-22
CA2979506A1 (en) 2016-09-22
TWI769586B (zh) 2022-07-01
AU2020220070A1 (en) 2020-09-03
CR20210233A (es) 2021-06-25
AU2020220070B2 (en) 2021-12-02
UA123392C2 (uk) 2021-03-31
AU2016232140A1 (en) 2017-09-07
AR121588A2 (es) 2022-06-22
KR20170126929A (ko) 2017-11-20
TW201643187A (zh) 2016-12-16
MA46647A1 (fr) 2021-10-29
US20180207251A1 (en) 2018-07-26
KR102718168B1 (ko) 2024-10-15
PE20171515A1 (es) 2017-10-20

Similar Documents

Publication Publication Date Title
SG10202001404VA (en) Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
IL257331A (en) New peptides and combinations of peptides for use in immunotherapy against prostate cancer and other types of cancer
IL256189A (en) New peptides and combinations of peptides used in immunotherapy against ovarian cancer and other types of cancer
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
SG10202001665QA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
IL258599A (en) New peptides and a combination of peptides used in immunotherapy against breast cancer and other types of cancer
ZA201707810B (en) Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
ZA201800129B (en) Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
SG10202005950XA (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
IL256160A (en) New peptides and their combination for use in immunotherapy and methods for creating scaffolds for use against pancreatic cancer and other types of cancer
GB201604458D0 (en) Peptides and combination of peptides for use in immunotherapy against cancers
GB201604490D0 (en) Peptides combination of peptides for use in immunotherapy against cancers
IL258609A (en) New peptides and a combination of peptides for use in immunotherapy against several types of cancer
IL254081B (en) New peptides and a combination of peptides for immunotherapeutic use against pancreatic cancer and other types of cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)